Advertisement

Tijdschrift voor Kindergeneeskunde

, Volume 78, Issue 2, pp 69–73 | Cite as

Hevige pijnklachten aan handen en voeten bij koorts en huidafwijkingen: de ziekte van Fabry

  • M.G. Bouwman
  • F.A. Wijburg
  • S.M. Rombach
  • G.E. Linthorst
  • C.E.M. Hollak
  • J.M.F.G. Aerts
Article
  • 18 Downloads

Samenvatting

De ziekte van Fabry is een zeldzame X-gebonden lysosomale stapelingsziekte. Vanwege de zeldzaamheid van de ziekte en de atypische verschijnselen wordt de diagnose meestal pas laat gesteld. Op volwassen leeftijd leidt de ziekte tot aanzienlijke morbiditeit en mortaliteit. Gezien de nieuwe therapeutische mogelijkheden en veranderende inzichten is vroege opsporing van de ziekte van belang. De kenmerkende klachten en verschijnselen op de kinderleeftijd zijn: (1) hevige pijnklachten in de handen en voeten (acroparesthesieën), (2) het onvermogen om goed te zweten (hypohidrosis of anhidrosis), (3) kenmerkende huidafwijkingen (angiokeratomen) en (4) gastro-intestinale klachten (buikpijn en diarree). Het ziektebeeld wordt geïllustreerd met een casus.

Summary

Fabry disease is a rare X-linked lysosomale storage disorder, causing significant morbidity and a reduced life-span in adults. Diagnosis of Fabry disease is often delayed. However, early diagnosis is warranted to initiate timely therapeutic intervention and follow-up. In children, Fabry disease is characterized by (1) severe pains in hands and feet (acroparesthesia), (2) inability to sweat (anhydrosis), (3) angiokeratoma, and (4) gastro-intestinal complaints (abdominal pain and diarrhea). The disease will be illustrated by a case report.

Literatuur

  1. 1.
    Vedder AC, Linthorst GE, Breemen MJ van, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007;30:68–78.CrossRefPubMedGoogle Scholar
  2. 2.
    Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular basis of inherited disease, 8th ed. New York: McGraw-Hill, 2001.Google Scholar
  4. 4.
    Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006; 79:31–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Banikazemi M, Bultas J,Waldek S, et al. Agalsidasebeta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77–86.PubMedGoogle Scholar
  6. 6.
    Weidemann F, Niemann M, Breunig F, et al. Longterm effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009; 119:524–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–35.CrossRefPubMedGoogle Scholar
  9. 9.
    Dobrovolny R, Dvorakova L, Ledvinova J, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med. 2005; 83:647–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95:86–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008; 64:550–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Pediatrics. 2005;115:e344–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Kampmann C, Wiethoff CM, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr. 2008; 97:463–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009; 40:788–94.CrossRefPubMedGoogle Scholar
  16. 16.
    Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51:767–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta. 2005;353:201–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9–16.CrossRefPubMedGoogle Scholar
  19. 19.
    Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285: 2743–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Schiffmann R, Ries M, Timmons M, et al. Longterm therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21:345–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Wilcox WR, Banikazemi M, Guffon N, et al. Longterm safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75:65–74.CrossRefPubMedGoogle Scholar

Copyright information

© Bohn, Stafleu van Loghum 2010

Authors and Affiliations

  • M.G. Bouwman
    • 1
  • F.A. Wijburg
    • 1
  • S.M. Rombach
    • 1
  • G.E. Linthorst
    • 1
  • C.E.M. Hollak
    • 2
  • J.M.F.G. Aerts
    • 3
  1. 1.Emma KinderziekenhuisAmsterdamThe Nederlands
  2. 2.afdeling Interne GeneeskundeEndocrinologie en MetabolismeAmsterdamThe Nederlands
  3. 3.afdeling Medische BiochemieAmsterdam Lysosome Center ‘Sphinx’, AMCAmsterdamThe Nederlands

Personalised recommendations